GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of ...

Opens in a new tab or window GLP-1 receptor agonist or SGLT2 inhibitor prescribing became ... in characteristics for patients prescribed these drug suggest their use "was intended to address ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

Merck and Pfizer are to take on the crowded SGLT2 ... day at list price. The US approval has achieved, the companies await similar clearance in Europe, the other leading market for the drugs.

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

"If we want to maximize the benefits of SGLT2 [inhibitors], we need to start patients on them early, keep them on them, and not stop the drug," Herrington said at the late-breaking session.

Olezarsen, an investigational ligand-conjugated antisense medication, was designed to inhibit the production ... Sotagliflozin is a dual sodium-glucose co-transporter types 1 and 2 (SGLT1, SGLT2) ...

Because this list isn't complete ... If you have type 2 diabetes, you can choose a similar SGLT2 inhibitor to Jardiance, such as Invokana (canagliflozin). Because both drugs stop a protein that ...